Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused
on developing and commercializing innovative small-molecule drugs for
the treatment of immune mediated disease and cancer. Our pharmaceutical
drug development candidates are synthetic small-molecules designed to
target key biochemical pathways involved in human diseases with critical
unmet needs. We currently have four proprietary drug candidates under
clinical development and one drug candidate under preclinical
Close
PreclinicalStudies done in animals or in cell cultures to show that a new drug should be tested in humans.
development, and a lead compound undergoing preclinical optimization. ClosePreclinical optimizationDeveloping experiments in the lab to optimize potential clinical results.
This includes a histone deacetylase inhibitor (PCI-24781) about to enter
a Phase II clinical trial; ClosePhase II Clinical TrialIn this phase of testing, doctors try to confirm the safety and dosing of the new drug as well as its effectiveness. an inhibitor of Factor VIIa CloseFactor VIIa, Factor IXa, Factor Xa, Factor XIA series of coagulation factors that are circulated outside the blood stream, and are within the microscopic or cellular environment surrounding tumors. (PCI-27483) soon
to be in a Phase II clinical trial; an inhibitor of Bruton's tyrosine
kinase CloseKinaseAn enzyme that activates other enzymes.
(Btk) (PCI-32765) currently in a Phase I clinical trial ClosePhase I Clinical TrialOne of the steps involved in the drug approval process. In this phase, doctors try to establish the safety of the new drug, the best dose to give and the best way to give it. They also begin to get information showing how much the new drug could benefit patients. targeting
oncology CloseOncologyThe study and treatment of cancer.
applications; a Btk inhibitor in advanced preclinical lead
optimization and testing targeting autoimmune CloseAutoimmuneAn immune response by the body against one of its own cells or tissues.and allergic indications;
and an HDAC8 inhibitor lead (PCI-34051) that is currently being
optimized for autoimmune and cancer indications. Motexafin gadolinium
(MGd) is now in a Phase 2 trial being conducted by the National Cancer
Institute (NCI) in patients with primary brain tumors.